Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Background/AimsTofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE...

Full description

Bibliographic Details
Main Authors: Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2018-04-01
Series:Intestinal Research
Subjects:
Janus kinase
Colitis, ulcerative
Clinical trials
Online Access:http://www.irjournal.org/upload/pdf/ir-16-233.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-16-233.pdf

Similar Items